Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics

Completed · Phase 2

Conditions studied: Asthma

In brief

This study is designed to evaluate the single-dose effectiveness of two bronchodilator inhalers given at two dose levels in pediatric asthma patients.

Key facts

Study ID

NCT00112411

Run by

Teva Branded Pharmaceutical Products R&D, Inc.

Starts

2005-06-30

Expected to finish

2005-09-30

Last updated by the study team

2021-12-08

Who can join

Age: 4 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Persistent asthma for a minimum of six months duration that has been stable for at least four weeks
• Predicted FEV1 60-90%
• Demonstration of 12% airway reversibility

You may not qualify if…

• Continuous requirement for beta-blockers, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants, anticholinergics and/or steroids other than those inhaled;
• Presence of clinically-significant non-asthmatic acute or chronic disease

Where it is running

• Allergy Associates Medical Group, Inc. — San Diego, California, United States
• Aeroallergy Research Labs of Savannah, Inc. — Savannah, Georgia, United States
• University of Louisville — Louisville, Kentucky, United States
• Northeast Medical Research Associates, Inc. — North Dartmouth, Massachusetts, United States
• Mississippi Asthma and Allergy Clinic — Jackson, Mississippi, United States
• North Carolina Clinical Research — Raleigh, North Carolina, United States
• Allergy and Asthma Research Group — Eugene, Oregon, United States
• Allergy Associates Research Center — Portland, Oregon, United States
• Medical Research Network — The Woodlands, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.